Atezolizumab Plus Bevacizumab Combination Therapy Compared to Sorafenib and Atezolizumab Monotherapies for Treatment of Unresectable or Metastatic Hepatocellular Carcinoma

Background/Aim

• Sorafenib has been the historical first-line treatment of choice for unresectable or metastatic hepatocellular carcinoma (HCC) since 2007. 

• However, on May 29, 2020, FDA approved atezolizumab plus bevacizumab (AB) combination for HCC and gave it priority over sorafenib. 

• Here, we performed a systematic review evaluating the efficacy and safety of combination immunogenic chemotherapy as first-line therapy as opposed to sorafenib (S) and atezolizumab (A) monotherapies.